The federal Project Grant award R01AI186809 for $1,314,572, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to Yale University, aims to develop a novel HIV cure strategy using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The key products and services to be delivered include:
-
Investigating the ability of CD4MC/Ab interventions to eliminate the HIV reservoir and enable sustained virus control in new-generation humanized mouse models, using advanced single-cell analysis techniques to characterize immune cells and virus-infected cells.
-
Formulating a highly effective CD4MC/Ab cocktail by screening patient plasma to identify additional potent CD4I Ab families to synergize with the CD4MCs.
-
Systematically exploring how viral envelope properties influence HIV reservoir establishment and susceptibility to elimination by the CD4MC/Ab cocktails in humanized mouse models.
The overarching goal is to develop a CD4MC/Ab-based early intervention cure strategy for HIV-1 that could ultimately inform future clinical trials and advance the field of HIV cure research.
Generated 3/18/25, 3:58 AM